Business
Voyageur Pharmaceuticals Initiates First Commercial Shipments of Barium Contrast Products to Canadian Clinics
(TheNewswire) Calgary, Alberta, Canada – August 21, 2025 – TheNew...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Initiates First Commercial Shipments of Barium Contrast Products to Canadian Clinics \n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Calgary, Alberta, Canada – August 21, 2025 –\n \n\n TheNewswire -\n \n\n Voyageur\nPharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (\"Voyageur\"\nor the \"Company\"), a radiology contrast media company\nfocused on vertical integration and supply chain security, today\nannounces the first commercial delivery of the full suite of\nVoyageur’s Health Canada–approved barium contrast products.\nFurther to the Company's news release dated June 4, 2025, the\ndelivery was to a leading Canadian radiology provider who signed a\npurchase order in June 2025. Voyageur's product line is currently\nbeing evaluated by other private clinics, group purchase organizations\nand Provincial Health Care procurement groups.\n \n\n\n\n The order follows successful product evaluations and\nregulatory milestones, with Voyageur hitting its milestone to deliver\nproduct by the end of August.\n \n\n\n\n “This sale has many important aspects for the\ndevelopment of the Frances Creek project and anticipated global\nexpansion,” said Brent Willis, President and CEO. “The data\naccumulated from the use of our products will be a critical component\nof our FDA filings to enter the US market and is expected to provide\nthe economics to complete our final feasibility study to advance the\nFrances Creek project towards production.“\n \n\n\n\n Approved Product Line Now\nCommercialized\n \n\n\n\n Voyageur’s approved barium contrast agents are\noptimized for a range of gastrointestinal imaging applications:\n \n\n\n\n\n\n SmoothX (2%w/v):\n \n\n For CT imaging of the GI tract; noted for its improved taste\nand tolerability.\n \n\n\n\n\n\n SmoothHD® 105%:\n \n\n High-density suspension for upper GI and double contrast\nstudies; delivering sharp mucosal detail.\n \n\n\n\n\n\n\n\n SmoothLD®\n \n\n (60%\nw/v):\n \n\n Low-density suspension for single contrast\nGI studies.\n \n\n\n\n\n\n\n\n VisionHD®\n \n\n (98%\nw/w):\n \n\n Powdered high-density suspension for upper\nGI double-contrast imaging.\n \n\n\n\n\n\n\n\n VisionLD®\n \n\n (96%\nw/w):\n \n\n Powdered low-density suspension for single\...